|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Implication of the Hedgehog pathway in hepatocellular carcinoma显示文摘The prognosis for patients who are diagnosed with advanced stage hepatocellular carcinoma(HCC)is poor because there are few treatment options.Recent research has focused on the identification of novel molecular entities that can be targeted to inhibit oncogenic signals that are involved in the carcinogenesis,proliferation and progression of HCC.Among all of the pathways that are involved in the development of HCC,Hedgehog(HH)signalling has demonstrated a substantial role in hepatocarcinogenesis and HCC progression.HH plays a physiological role in embryogenesis,through the induction of the differentiation of hepatocytes from endodermal progenitors.The re-activation of the HH pathway in chronic damaged liver is a mechanism of fibrotic degeneration and is implicated in various stages of HCC development.HH activation sustains the subpopulation of immature liver epithelial cells that are involved in the pathogenesis of cirrhosis and HCC,and HH itself is a mediator of the alcohol-derived malignant transformation of liver cells.High levels of expression of HH protein markers in liver tumour tissues are correlated with aggressive histological and biological features and a poor clinical outcome.In vitro and in vivo inhibition models of the HH pathway confirm that HH is essential in maintaining tumour growth,metastasis and a mesenchymal phenotype. | Carminia Maria Della Corte Giuseppe Viscardi Federica Papaccio Giovanna Esposito Giulia Martini Davide Ciardiello Erika Martinelli Fortunato Ciardiello Floriana Morgillo | 2017 | World Journal of Gastroenterology2017，23，24： | 10 |
| 2 | Present and future of metastatic colorectal cancer treatment: A review of new candidate targets显示文摘In the last two decades, great efforts have been made in the treatment of metastatic colorectal cancer(m CRC) due to the approval of new target agents for cytotoxic drugs. Unfortunately, a large percentage of patients present with metastasis at the time of diagnosis or relapse after a few months. The complex molecular heterogeneity of this disease is not completely understood; to date, there is a lack of predictive biomarkers that can be used to select subsets of patients who may respond to target drugs. Only the RAS-mutation status is used to predict resistance to anti-epidermal growth factor receptor agents in patients with m CRC. In this review, we describe approved targeted therapies for the management of metastatic m CRC and discuss new candidate targets on the horizon. | Giulia Martini Teresa Troiani Claudia Cardone Pietropaolo Vitiello Vincenzo Sforza Davide Ciardiello Stefania Napolitano Carminia Maria Della Corte Floriana Morgillo Antonio Raucci Antonio Cuomo Francesco Selvaggi Fortunato Ciardiello Erika Martinelli | 2017 | World Journal of Gastroenterology2017，23，26： | 7 |
| 3 | Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi‐targeted kinase inhibitors in pimasertib‐resistant human lung and colorectal cancer cells显示文摘 | Erika Martinelli Teresa Troiani Elena D’Aiuto Floriana Morgillo Donata Vitagliano Anna Capasso Sarah Costantino Loreta Pia Ciuffreda Francesco Merolla Loredana Vecchione Veerle Vriendt Sabine Tejpar Anna Nappi Vincenzo Sforza Giulia Martini Liberato Berri | 2013 | Int J Cancer2013，，9： | 2 |
| 4 | Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib显示文摘 | Morgillo F Woo JK Kim ES | 2006 | Cancer Res2006，66，10： | 1 |
| 5 | Sequence-dependent,synergistic antiproliferative and proapoptic effects of the combination of cytotoxic drugs and enzastaurum,a protein kinase Cβ inhibitor in non-small cell lung cancer cells显示文摘 | Morgillo F Martinelli E Troiani T | 2008 | Mol Cancer Ther2008，17，6： | 1 |
| 6 | Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib显示文摘 | MORGILLO F WOO J K KIM E S | 2006 | Cancer Res2006，66，10： | 1 |
| 7 | Heterodimerization of in- sulin-like growth factor receptor/epidermal growth factor re- ceptor and induction of surviving expression counteract the an titumor action of erlotinib 显示文摘 | Morgillo F Woo JK Kim ES | 2006 | Cancer Res2006，66，10： | 1 |
| 8 | Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib显示文摘 | MORGILLO F KIM W Y KIM E S | 2007 | Clin Cancer Res2007，13，9： | 1 |
| 9 | Chronic inflammation and oxidative stress in human carcinogenesis显示文摘 | Federico A Morgillo F Tuccillo C | 2007 | Int J Cancer2007，121，11： | 1 |
| 10 | Panitumumab , the evidence of its therapeutic potential in metastatic colorectal cancer care 显示文摘 | Martinelli E Morgillo F Troiani T | 2007 | Core Evid2007，2，2： | 1 |
| 11 | Implications for KRAS status and EGFR-targeted therapies in metastatic CRC显示文摘 | Normanno N Tejpar S Morgillo F | 2009 | Nat Rev Clin Oncol2009，6，9： | 1 |
| 12 | Heterodimerization of insulinlike growth factor receptor/epidermal growth factor receptor and induction of surviving expression counteract the antitumor action of erlotinib显示文摘 | Morgillo F Woo JK Kim ES | 2006 | Cancer Res2006，66，10： | 1 |
| 13 | Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKBI wild-type NSCLC cell lines显示文摘 | Morgillo F Sasso FC Della Corte CM | 2013 | Clin Cancer Res2013，19，13： | 1 |
| 14 | Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib显示文摘 | Woo JK Kim ES | 2006 | Cancer Res2006，66，10： | 1 |
| 15 | A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients:treatment rationale and protocol dynamics显示文摘 | Gridelli C Rossi A Morgillo F | 2007 | Clin Lung Cancer2007，8，9： | 1 |
| 16 | Implication of the insulin- like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib 显示文摘 | Morgillo F Kim WY Kim ES | 2007 | Clin Cancer Res2007，13，9： | 1 |
| 17 | Heterodimerization of insulin- like growth factor receptor/epidermal growth factor receptor and in- duction of survivin expression counteract the antitumor action of er- lotinib显示文摘 | Morgillo F Woo JK Kim ES | 2006 | Cancer Res2006，66，10： | 1 |
| 18 | Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy 显示文摘 | Morgillo F Bareschino MA Bianco R | 2007 | Differentiation2007，75，9： | 1 |
| 19 | Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer ceils to treatment with gefitinib 显示文摘 | Morgillo F Kim W Y Kim E S | 2007 | Clin Cancer Res2007，13，9： | 1 |
| 20 | Sequence-dependent,synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin,a protein kinase C beta inhibitor,in non-small cell lung cancer cells 显示文摘 | Morgillo F Martinelli E Troiani T | 2008 | Mol Cancer Ther2008，7，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员